Critical Challenges and
Landmark Practice Advances
in Multiple Sclerosis

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

June 1, 2009

Expiration Date:

June 1, 2011

Intended Audience:

The educational activity is designed for all physi cians, nurses, NPs, academicians, pharmacists, re searchers, investigators, and program directors from the fields of multiple sclerosis, neurology, immunol ogy, and hospital pharmacy. It is directed toward all members of the MS multidisciplinary team caring for patients with this disease state.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant from Teva Neuroscience, Inc.
 

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Jerry S. Wolinsky, MD – Program Chairman
Bartels Family and Opal C. Rankin Professor of Neurology
Director, Multiple Sclerosis Research Group
University of Texas Health Science Center at Houston
Houston, TX

Grant/Research: National Institutes of Health, sanofi-aventis, Clayton Foundation for Research
Consultant: Teva Pharmaceuticals, Teva Neurosciences, Genentech, Inc., sanofi-aventis, Bayer, EMD Serono, Glycominds, Novartis, Antisense Therapeutics, Ltd., UCB, Novartis

Kenneth P. Johnson, MD
Professor of Neurology
Director, Maryland Center for Multiple Sclerosis
University of Maryland Medical Center
Baltimore, MD

Consultant: Teva Pharmaceuticals
Speaker’s Bureau: Teva Pharmaceuticals

Andrew D. Goodman, MD
Professor of Neurology
Director, Multiple Sclerosis Center
Chief, Neuroimmunology Unit
Department of Neurology
University of Rochester Medical Center
Rochester, NY

Consultant: Bayer, Biogen-Idec, EMD Serono, Genetech, Genzyme, Pfizer, Teva
Grant/Research: Acorda,, Bayer, EMD Serono, Genzyme, Teva

Daniel Pelletier, MD
Associate Professor of Neurology
Advanced Imaging in Multiple Sclerosis (AIMS) Laboratory
University of California San Francisco

Nothing to Disclose

Educational Objectives:

Participants in this CME-certified WebCAST will:

• Learn to diagnose MS early, identify clinically isolated syndrome (CIS), and determine indica tions and triggers for early treatment with immune-modulating agents.

• Learn how to sequence drug therapy using immune-modulating agents, with an em phasis, when appropriate, on their deployment as initial, monotherapeutic agents in relapsing-remitting multiple sclerosis RRMS, and their role in patients who have therapeutic failures with other agents.

• Learn about the value of immunomodulatory therapy in producing sustained reductions in the relapse rate without an increase in neurologic disability.

• Learn about the long-term efficacy and safety of immune-modulating disease agents in (RRMS) patients who remain on such therapy, focusing on reduction of progression of disability as evaluated by EDSS scores and other parameters.

• Learn about the importance of early treatment of MS and the MRI/imaging manifestations (accumulation of enhancing brain lesions characteristic of MS) of delaying therapy with immune-modulating disease agents in patients with RRMS.

Disclaimer:

Copyright © 2009 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2009 All rights reserved